Frequently Asked Questions
- Where is NEMOS available?
NEMOS is approved for the European market only.* The device is available in Germany, Austria and Italy.
Information on the availability in other European countries is available on request.
* All countries of the European Union and Switzerland
- Why NEMOS?
Additional therapy optionWith NEMOS there is another promissing and easy therapy option available for patients suffering from epilepsies.
Easy patient carePatients carry out the treatment autonomously. There's no need for additional or longer doctors' appointments.
No surgical interventiont-VNS therapy with NEMOS provides targeted stimulation of the vagus nerve, without the risks of a surgical intervention.
Minor side effectst-VNS is a therapeutic alternative with minor side effects. An analysis of data from over 300 patients and volunteers, who participated in studies of t-VNS, showed potential side effects that include itching, dysaesthesia, and local pain at the stimulation site. These side effects usually disappear soon after stopping the stimulation.*
* Vigilance data cerbomed GmbH
- How does NEMOS work?
t-VNS treatment uses the transcutaneous vagus nerve stimulator NEMOS. NEMOS consists of a stimulation unit and a dedicated ear electrode. The stimulation unit, having approximately the size of a common mobile phone, sends out the electrical impulses. It is connected with the ear electrode, which patients wear like an earphone. The impulses are transferred via ear electrode through the skin to a the auricular branch of the vagus nerve.
- How often should NEMOS be used?
Patients treat themselves with t-VNS in sessions lasting approximately 4 hours per day.
- How does t-VNS work?
Transcutaneous Vagus Nerve Stimulation (t-VNS) uses the fact that the auricular branch of the vagus nerve (ABVN) supplies the skin of the concha in the human ear.3 This allows for transcutaneous electrical stimulation of the nerve fibers in this area. Intensity, pulse duration and frequency of the t-VNS stimulation have been optimized to induce signals in thick-myelinated Aß fibres of the ABVN. Like those of the cervical branch of the vagus nerve, these project directly to the nucleus of the solitary tract (NTS) in the brainstem.4,5 The NTS is the starting point to activate a complex cerebral network, corresponding closely to that targeted by invasive VNS, and associated with the anticonvulsive effect.1,2,6
- Beekwilder JP, Beems T: Overview of the clinical applications of vagus nerve stimulation. J Clin Neurophysiol 2010;27:130-138.
- Amar AP, Levy ML, Liu CY, Apuzzo MLJ: Vagus Nerve Stimulation; in Krames ES, Peckham PH, Rezai AR, (eds): Neuromodulation. London, Academic Press, 2009, pp 625-637.
- Peuker ET, Filler TJ: The nerve supply of the human auricle. Clin Anat 2002;15:35-37.
- Nomura S, Mizuno N: Central distribution of primary afferent fibers in the Arnold's nerve (the auricular branch of the vagus nerve): a transganglionic HRP study in the cat. Brain Res 1984;292:199-205.
- Gao XY, Rong P, Ben H, Liu K, Zhu B, Zhang S: Morphological and electrophysiological characterization of auricular branch of vagus nerve: Projections to the NTS in mediating cardiovascular inhibition evoked by the acupuncture-like stimulation; 2010, p 694.22.
- Vonck K, Boon P, Van RD: Anatomical and physiological basis and mechanism of action of neurostimulation for epilepsy. Acta Neurochir Suppl 2007;97:321-328.
- Which side effects may occur?
t-VNS is a therapeutic alternative with minor side effects. An analysis of data from over 300 patients and volunteers, who participated in studies of t-VNS, showed potential side effects that include itching, dysaesthesia, and local pain at the stimulation site. These side effects usually disappear soon after stopping the stimulation.*
* Vigilance data cerbomed GmbH
- Which contraindications do exist?
The NEMOS device is not certified for treating patients during pregnancy, or for patients with active implants (such as a cardiac pacemaker, or a cochlear implant). The device must not be used on wounds and diseased skin in the area of the electrodes.
- How effective is therapy with NEMOS?
Like most pharmaceutical and neuromodulatory treatments for epilepsies, t-VNS is not an acute therapy. Even if you respond to therapy with NEMOS, the effect may occur with a latency of some weeks to a few months. Like in all other therapies there can never be a guarantee of success for a treatment using NEMOS. It is possible that some patients will not respond sufficiently to the therapy. Such patients can return the device after 6 months, for a partial refund of the purchase price.
t-VNS® - for treatment of drug-resistant epilepsy
Please download our brochure for health professionals.
Please note: NEMOS® is not cleared or approved for use in the U.S.